Skip to main content

Table 2 Population characteristics

From: The effects of recreational cannabis use on glycemic outcomes and self-management behaviours in people with type 1 and type 2 diabetes: a rapid review

First author, year Sample size, mean age (SD), gender/sex distributiona Type of diabetes; duration of illnessb [years, mean (SD)] Diabetes treatment Comorbidities/complications Exclusion criteria
Akturk, 2019 [21] Group 1: 134, 31.3 (11.1), 55.2% female
Group 2: 316, 39.1 (14.2), 40.2% female
Group 1: TID; 16.3 (–) years
Group 2: TID; 20.9 (–)
Continuous glucose monitoring: 45.% Group 1, 55.1%
Group 2
Insulin pump: 50.7% Group 1, 66.5% Group 2
Patients with diabetes other than T1D, pregnancy, and repeat follow-up visits within the study duration
Helgeson, 2016 [22] 132, 23 (–), 56% female TID; 15.8 (--) Insulin (units/day):
median 50 (IQR 30-65)
Insulin pump therapy:
79/183 (43%)
Indications of neuropathy (vibratory thresholds above age-specific norms): 17%;
uACR above 30 mg/g: 7%
Hogendorf, 2016 [23] 209, 16.5 (1), 48.8% female, 51.2% male TID; 6.5 (4.4) Age 15–18 years
Thurheimer-Cacciotti, 2017 [24] 75, 24.3 (4.1), 100% female TID–
Winhusen, 2018 [25] 1184
– (–),
T2D –
Wisk, 2018 [26] 138
20.5 (1.5)
80.40% female
T2D, 10.9 (5.2)^ Insulin pump users: 84.1%
Testing blood sugar > 5 times/day: 44.2%
> 3 HbA1c tests in the past year: 65.9%
Average last HbA1c: 7.6
  1. SD standard deviation, IQR interquartile range, T1D type 1 diabetes, uACR urinary albumin/creatinine ratio, HbA1c glycated hemoglobin
  2. aValues are provided as reported in the studies; calculations for missing values have not been conducted to avoid assumptions regarding the gender distribution of study samples
  3. bAll studies reported the mean duration of illness except where indicated by ^which reported the age at diagnosis [years, mean (SD)]